{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
    "indicator": {
      "slug": "sales-growth-at-constant-exchange-rates",
      "name": "Sales growth at constant exchange rates",
      "definition": "Percentage change in sales calculated at constant exchange rates over the specified period."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "JP",
      "name": "Japan",
      "type": "country"
    },
    "period": {
      "start": "2026-01-01",
      "end": "2026-06-30",
      "type": "quarter"
    },
    "value": 11,
    "value_text": "+11%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "Roche",
      "org_short_name": "Roche",
      "org_url": "https://www.roche.com",
      "org_tier": 2,
      "document_title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...",
      "document_url": "https://www.roche.com/media/releases/med-cor-2026-07-23",
      "document_type": "press_release",
      "locator": "Group results",
      "quote": "In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra.",
      "published_date": "2026-07-23",
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB",
      "bibtex": "@misc{roche2026salesbjmgeb,\n  author       = {{Roche}},\n  title        = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\\% sales growth at constant exchange rates; -2\\% in CHF due to the significant a...},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGEB},\n  note         = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}